US8876849B2 - False lumen occluder - Google Patents

False lumen occluder Download PDF

Info

Publication number
US8876849B2
US8876849B2 US13/170,843 US201113170843A US8876849B2 US 8876849 B2 US8876849 B2 US 8876849B2 US 201113170843 A US201113170843 A US 201113170843A US 8876849 B2 US8876849 B2 US 8876849B2
Authority
US
United States
Prior art keywords
struts
strut portion
intraluminal device
mid
intraluminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/170,843
Other languages
English (en)
Other versions
US20120022573A1 (en
Inventor
Jarin Kratzberg
Sharath Gopal
James D. Purdy
Blayne A. Roeder
Steven J. Charlebois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cook Medical Technologies LLC
Original Assignee
Cook Medical Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cook Medical Technologies LLC filed Critical Cook Medical Technologies LLC
Priority to US13/170,843 priority Critical patent/US8876849B2/en
Priority to EP11174324.1A priority patent/EP2409655B1/en
Priority to CN201110208363.0A priority patent/CN102415909B/zh
Priority to JP2011158746A priority patent/JP5912317B2/ja
Assigned to COOK MEDICAL TECHNOLOGIES LLC reassignment COOK MEDICAL TECHNOLOGIES LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC.
Assigned to MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC. reassignment MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOPAL, SHARATH, KRATZBERG, JARIN, CHARLEBOIS, STEVEN J., PURDY, JAMES D., ROEDER, BLAYNE A.
Publication of US20120022573A1 publication Critical patent/US20120022573A1/en
Publication of US8876849B2 publication Critical patent/US8876849B2/en
Application granted granted Critical
Assigned to WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT reassignment WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COOK MEDICAL TECHNOLOGIES LLC
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A61B17/12113—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel within an aneurysm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
    • A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape

Definitions

  • Aortic dissection is a condition that affects the aorta, which is the largest artery in the body. This condition is caused by the separating/dissection of the individual layers of the aorta, where the inner layer of the aortic wall tears, or peels, away from the adjacent layer of the aorta. This separation of the layers creates an area, or a pathway, between the torn-away layer and the remainder of the aortic wall. The area created by the two layers is called a false lumen. As blood flows through the aorta, it travels through its normal pathway, referred to as the true lumen, but a portion of the blood also is directed into the false lumen.
  • the false lumen is a secondary flow path that does not provide any blood delivery to the remainder of the body.
  • the rate of blood flow and volume of diverted blood into the false lumen can result in the exertion of large forces against the aortic wall. These forces result in the further propagation of the tear, thereby creating a larger false lumen and greater associated forces. The propagation of the tear can eventually lead the aorta wall to rupture, which can result in death.
  • the type of treatment for this condition depends on the severity and location of the aortic tear.
  • Medical therapy such as blood pressure and cholesterol-lowering drugs, are typically provided as one method of treatment for this condition. Medical therapy is designed to limit further propagation of the tear and to reduce the chances of aortic rupture. This type of treatment is adequate when the condition is in its early stages and no significant tear exists. However, it is not designed to prevent the further propagation of a dissected portion of the aortic wall.
  • Endovascular intervention is a minimally invasive procedure where a stent graft is placed within the damaged area. When expanded, the stent graft exerts a radial force along the damaged area, thereby forcing the dissected layer of the aorta against the adjacent layer of the aortic wall. In theory, retaining the dissected layer of the aorta against the adjacent layer of the aortic wall prevents blood from flowing into the dissected layer, thereby minimizing the blood flow into the false lumen.
  • This type of treatment only covers the dissected layer and sometimes does not fully occlude the false lumen formed between the dissected layer and the adjacent layer of the aortic wall.
  • This type of treatment is typically in chronic aortic dissection cases, there is a likelihood that blood will continue to flow between the dissected layer and the adjacent aortic layer, thereby causing the dissected portion of the aortic wall to further separate from the adjacent layer of the aortic wall which allows additional blood to reenter the false lumen.
  • Another disadvantage of this type of treatment is that it does not prevent the chances of future tears in the damaged area. As a result, endovascular repair is an inadequate method of treatment for patients suffering from chronic aortic dissection.
  • Open surgical repair is another type of treatment used to cure aortic dissection.
  • This highly invasive procedure requires the replacement of the diseased portion of the aorta with a Dacron/ePTFE graft.
  • the graft is sewn in the place of the removed portion of the aorta and on average requires a two-month recovery period.
  • open surgical repair is a lengthy procedure and subjects patients to a higher risk for stroke, ischemia, and other medical complications. As a result, this type of procedure is not recommended to treat aortic dissection cases unless no other treatment is available and carries a high likelihood of post-surgical complications.
  • the intraluminal device comprises a first end, a second end, and a central longitudinal axis between the first and second ends and expanded and compressed configurations, where a plurality of struts extend from the first to second end of the intraluminal device with at least one of the struts having a proximal strut portion, a distal strut portion, and a mid-strut portion between the proximal strut portion and the distal strut portion, where the mid-strut portion has at least two struts, and when the intraluminal device is in the expanded configuration, the plurality of struts are biased away from the longitudinal axis.
  • the intraluminal device comprises a first end, a second end, and a central longitudinal axis between the first and second ends and a expanded and compressed configurations, where a plurality of struts made from the same piece of material extend from the first to second end of the intraluminal device with at least one of the struts having a proximal strut portion, a distal strut portion, and a mid-strut portion between the proximal strut portion and the distal strut portion, where the mid-strut portion has at least two struts, and when the intraluminal device is in the expanded configuration, the plurality of struts are biased away from the longitudinal axis and the at least two struts of the mid-strut portion have an arcuate shape.
  • the intraluminal device comprises a first end, a second end, and a central longitudinal axis between the first and second ends and expanded and compressed configurations, where a plurality of struts made from the same piece of material extend from the first to second end of the intraluminal device with at least one of the struts having a proximal strut portion, a distal strut portion, and a mid-strut portion between the proximal strut portion and the distal strut portion, where the mid-strut portion has at least two struts made out of the same material as the plurality of struts, and when the intraluminal device is in the expanded configuration, the plurality of struts are biased away from the longitudinal axis and the at least two struts of the mid-strut portion have an arcuate shape.
  • FIG. 1 shows a side view of one embodiment of an intraluminal device having a plurality of struts in an expanded configuration.
  • FIG. 2 shows a side view the intraluminal device shown in FIG. 1 in a compressed configuration.
  • FIG. 3 shows a front view of the intraluminal device shown in FIG. 1 when in the compressed configuration.
  • FIG. 4 shows a front view of the intraluminal device shown in FIG. 1 when in the expanded configuration.
  • FIG. 5 shows another embodiment of the intraluminal device having a plurality of independent struts in an expanded configuration.
  • FIG. 6 shows a cross-sectional view of a false lumen within the aorta.
  • FIG. 7 shows one embodiment of a deployment device for the intraluminal device.
  • FIG. 8 shows another embodiment of the deployment device of the intraluminal device.
  • FIG. 9 shows the deployment device entering a vessel and a false lumen within the aorta.
  • FIG. 10 shows the deployment of the intraluminal device within the false lumen shown in FIG. 9 .
  • FIG. 11 shows the intraluminal device secured within the false lumen shown in FIG. 9 .
  • FIG. 12 shows the intraluminal device in a compressed configuration within the false lumen shown in FIG. 9 .
  • FIG. 13 shows another embodiment of the intraluminal device wrapped in a membrane.
  • distal with respect to such a device, or false lumen occluder, is intended to refer to a location that is, or a portion of the device that when implanted, is further downstream with respect to blood flow; the term “distally” means in the direction of blood flow or further downstream.
  • proximal is intended to refer to a location that is, or a portion of the device that when implanted is, further upstream with respect to blood flow; the term “proximally” means in the direction opposite to the direction of blood flow or further upstream.
  • intraluminal describes objects that are found or can be placed inside a lumen in the human or animal body.
  • a lumen can be an existing lumen or a lumen created by surgical intervention. This includes lumens such as blood vessels, such as an aorta, parts of the gastrointestinal tract, ducts such as bile ducts, parts of the respiratory system, etcetera.
  • “Intraluminal device” is thus a device that can be placed inside one of these lumens.
  • An expandable device having a plurality of struts is a type of intraluminal device.
  • This invention relates to an intraluminal device having a plurality of struts extending from a first end of the device to the second end of the device. Along at least one of the struts is a mid-strut portion having two secondary struts.
  • the method of delivery and placement of the intraluminal device within a lumen is also part of the invention described herein.
  • an intraluminal device 10 in an expanded configuration is shown.
  • the intraluminal device 10 includes a first end 12 and a second end 14 , where the first end 12 and second end 14 are along a central longitudinal axis A.
  • a plurality of struts 16 extend from the first end 12 to the second end 14 and are made out of a single piece of material.
  • Each of the plurality of struts 16 include a proximal portion 18 that is adjacent to the first end 12 and a distal portion 20 that is adjacent to the second end 14 of the intraluminal device 10 .
  • there are 16 struts 16 there are 16 struts 16 , however the number of struts 16 in a particular embodiment may vary and can range anywhere between 10 and 25.
  • each of the plurality of struts 16 further includes a mid-strut portion 22 .
  • the mid-strut portion 22 is located between the proximal strut portion 18 and the distal strut portion 20 for each strut 16 of the plurality of struts.
  • the mid-strut portion 22 of the strut 16 comprises two secondary struts 24 that diverge from the proximal portion 18 of the strut 16 and converge into the distal portion 20 of the same strut 16 .
  • the number of secondary struts 24 per each mid-strut portion 22 can vary anywhere between two, which is shown in the embodiment disclosed in FIG. 1 , up to, and including, six.
  • a single strut 16 may also have more than one mid-strut portion 22 , with each midstrut having two or more secondary struts 24 extending therefrom.
  • the secondary struts 24 permit expansion of the intraluminal device 10 to significantly larger diameters than would otherwise be possible with just a single strut, and also reduce the extent of foreshortening the intraluminal device 10 undergoes upon expansion.
  • the secondary struts 24 also contribute to enhanced stiffness of the intraluminal device 10 during loading, deployment and in vivo. Further, the secondary struts 24 increase the amount of metal in the intraluminal device 10 without contributing to the overall stiffness.
  • the number of secondary struts 24 in a particular embodiment may also vary.
  • one strut 16 may have zero secondary struts 24
  • another strut 16 may have two secondary struts 24
  • yet another strut 16 may have four secondary struts 24 , and so forth.
  • the relative locations and lengths of the mid-strut portion 22 with respect to the proximal stent portion 18 and distal stent portion 20 may vary and is application dependent. For example, depending on the desired location of secondary struts 24 relative to the first end 12 and the second end 14 of the intraluminal device 10 , the mid-strut portion 22 may be closer to one of the ends 12 , 14 . In addition, the length of each of the secondary struts 24 may also vary depending on the intended application. For example, in the embodiment shown in FIG. 1 , the mid-strut portion 22 is approximately one half the overall length of the strut 16 . This ratio may change depending on a particular application.
  • the struts 16 of the intraluminal device 10 are configured to expand and compress such that the struts 16 are substantially parallel to the longitudinal axis A when in the compressed configuration.
  • FIG. 2 depicts the intraluminal device 10 shown in FIG. 1 in a compressed configuration, where the struts 16 are substantially parallel to one another.
  • the intraluminal device 10 may have a length anywhere between 10-80 mm and an outer diameter of anywhere between 5-50 mm.
  • the length can vary from anywhere between 10-150 mm and have a compressed outer diameter of anywhere between about 5-18 Fr.
  • the intraluminal device 10 is intended to have minimal radial force (just enough to enable deployment within the false lumen).
  • the pattern shown in FIG. 1 is laser cut from a drawn, seamless tube, expanded to its final diameter and heat-set to retain the expanded shape.
  • the pattern consists of a series of struts 16 that run parallel to the long axis of the intraluminal device 10 , without any circumferential interconnections.
  • the struts 16 are bifurcated at approximately 1 ⁇ 3rd the distance from either end 12 , 14 of the intraluminal device 10 to form a pair of secondary struts 24 , intended to enhance stability.
  • the lack of circumferential interconnections is intended to reduce radial force and crush resistance.
  • the intraluminal device 10 is intended to have radial and flat plate crush resistance less than a typical stent graft (e.g., less than 15 N) used for treatment of aortic aneurysms or dissections. This is essential to promote thrombosis of the false lumen and stabilization and opening of the true lumen as the blood flow increases through the lumen.
  • a typical stent graft e.g., less than 15 N
  • each strut 16 has a length of 20 mm and a width of 220 ⁇ m and each of the two secondary struts 24 has a length of approximately 25 mm and a width of approximately 92 ⁇ m.
  • each of the two secondary struts 24 When in the expanded configuration, each of the two secondary struts 24 and form a 40 mm opening, or luminal diameter, 66 therebetween.
  • the dimensions of the secondary struts 24 of a particular strut 16 may depend on the number of secondary struts 24 for that particular embodiment. For example, if a particular strut 16 has two secondary struts 24 , the width of each secondary strut will approximately be one half of the width of the strut 16 . And if a particular strut 16 has three secondary struts 24 , the width of each secondary strut 24 will approximately be one third of the width of the strut 16 . However, this relationship between the number of secondary struts 24 and the width of the primary strut 16 is not required and there also may be instances where the width of each of the secondary struts 24 for a particular strut 16 may be not be equal to one another.
  • the intraluminal device 10 is made out of a single piece of material.
  • the types of material from which the intraluminal device 10 may be manufactured include a shape memory alloy comprised of Nickel and Titanium, which is commonly referred to as Nitinol, and Teritary alloys.
  • the intraluminal device 10 in this embodiment is manufactured out of a single cylindrical tube 26 .
  • the cylindrical tube 26 has a plurality of primary cuts 28 formed along the longitudinal axis A.
  • the primary cuts 28 form the struts 16 of the intraluminal device 10 .
  • Between each primary cut 28 is a secondary cut 30 , which also extends along the longitudinal axis A.
  • the secondary cuts 30 are not as long and wide as the primary cuts 28 and form the secondary struts 24 of the intraluminal device 10 .
  • the struts 16 and the secondary struts 24 have a rectangular-shaped cross-section.
  • the dimensions of the cuts 28 , 30 may vary between embodiments and within a single embodiment.
  • the respective lengths of each of the primary cuts 28 and secondary cuts 30 may vary in a single embodiment and the width of the cuts 28 , 30 may vary along a single cut, such that the width of the cut 28 , 30 may increase from the first end 12 as it approaches the mid-strut portion 22 and then decrease as it approaches the second end 14 , or vice versa, thereby affecting the shape and width of the struts 16 , 24 .
  • the path, or pattern, along which the cuts 28 , 30 are made is substantially parallel to the longitudinal axis A.
  • the cuts 28 , 30 may have a helical or a spiral-type path, or pattern, about the cylindrical tube 26 .
  • FIG. 4 is the intraluminal device 10 shown in FIG. 3 in the expanded configuration.
  • the struts 16 when in the expanded configuration, the struts 16 have an arcuate shape that bows away from the longitudinal axis A, and the secondary struts 24 of each strut 16 bias or bend away from one another.
  • the secondary struts 24 may bias away from each other in directions relative to the longitudinal axis, for example radially inward and outward.
  • one secondary strut 24 may bias toward the axis and the other away from the axis.
  • the secondary struts 24 may bias away from the longitudinal axis A and from one another in a radial direction.
  • the intraluminal device 10 When in the expanded configuration, the intraluminal device 10 is ellipsoidal in shape. It is contemplated that the intraluminal device 10 may have other shapes, such as a spherical shape, depending on the geometry and pattern of the struts 16 , 24 . When in the expanded configuration, the overall length of the intraluminal device 10 is less than when in the compressed configuration, and the maximum outside diameter of the intraluminal device 10 is greater than when in the compressed configuration.
  • the intraluminal device 10 is made of a plurality of independent struts 32 , each having a first end 34 and a second end 36 .
  • each of the first ends 34 of the independent struts 32 are held together via a first hub 38 and each of the second ends 36 of the independent struts 32 are held together via a second hub 40 .
  • the independent struts 32 in this embodiment may also have a mid-strut portion with secondary struts that is substantially the same as the mid-strut portion 22 and secondary struts 24 described above with respect to the first embodiments.
  • the intraluminal device 10 is intended to be placed into false lumen 42 of an aorta 44 , a pictorial representation of which is shown in FIG. 6 .
  • the false lumen 42 is a pocket created by a tear in the lining 46 of the aortic wall. A portion of the aortic lining 46 separates from an adjacent portion of the aortic lining 47 thereby forming a pocket. Blood flow is partially diverted into this pocket thereby creating a false lumen 42 . The pressure of the blood flow and collection of blood in this lumen 42 can cause the torn portion of the aortic lining 46 to propagate and eventually lead to the rupture of the aortic wall.
  • the intraluminal device 10 is loaded onto a deployment device 48 for insertion into a vessel.
  • the deployment device 48 includes a guide wire catheter 50 having a first end 60 with a nose cone dilator 52 attached thereto.
  • the intraluminal device 10 is located along a body 62 of the guide wire catheter 50 and may be radially compressed and secured thereto by two trigger wires 58 , which form loops around the intraluminal device 10 .
  • a sheath 56 is disposed over the guide wire catheter 50 and intraluminal device 10 . The sheath 56 assists the trigger wires 58 in retaining the intraluminal device 10 in the compressed configuration prior to deployment.
  • the sheath 56 alone may be sufficient to retain the intraluminal device 10 to the body 62 of the catheter 50 .
  • the superelastic property of Nitinol allows the struts 16 , 24 of the intraluminal device 10 to undergo considerable deformation, such as radial compression, yet return to their original shape when the compression force is removed.
  • a formulation of Nitinol comprising about 49.5% to 51.5% Nickel (atomic %) and about 50.5% to 48.5% Titanium is used (atomic %).
  • an equiatmoic formulation of Nitinol is used.
  • Additional formulations, consisting of ternary alloys e.g. Nitinol doped with 0.25 at % Chromium
  • the intraluminal device 10 may be placed in a compressed or collapsed configuration as shown in FIG. 9 , yet expand back to its original configuration when deployed from the deployment device 48 within the vessel.
  • the deployment device 48 includes a guide wire catheter 68 having a first end 70 and a second end 72 and a reduced diameter portion 76 adjacent to the second end 72 .
  • a cap 74 is disposed on the second end 72 and forms part of the guide wire catheter 68 .
  • the cap 74 forms a cavity 78 between it and the second end 72 in which a portion of the intraluminal device 10 may reside in the compressed configuration.
  • the intraluminal device 10 Prior to deployment, the intraluminal device 10 is positioned along the reduced diameter portion 76 and is retained by a sheath 56 and the cap 74 such that the intraluminal device 10 is retained in the compressed configuration.
  • FIGS. 9-11 depict the deployment of the intraluminal device 10 within a blood vessel, which in this instance is the aorta 44 .
  • a guide wire 54 is inserted through a femoral artery and is positioned within or adjacent to the false lumen 42 .
  • the guide wire 54 may be introduced via the subclavin artery into the aortic arch and positioned within or adjacent to the false lumen 42 .
  • the deployment device 48 is inserted along the guide wire 54 and positioned at a point of deployment within the false lumen 42 . Once the deployment device 48 reaches the desired point of deployment, the sheath 56 is retracted, as shown in FIG. 10 . Finally, the trigger wires 58 securing the intraluminal device 10 to the body 62 of the guide wire catheter 48 are disengaged from the intraluminal device 10 .
  • the intraluminal device 10 expands from its compressed configuration to its expanded configuration, as shown in FIG. 11 .
  • the sheath 56 may be retracted before the trigger wires 58 disengaged from the intraluminal device 10 .
  • the disengagement of the trigger wires 58 from the intraluminal device 10 will cause the intraluminal device 10 to expand into its expanded configuration as shown in FIG. 11 .
  • the outside diameter of the intraluminal device 10 when in the expanded configuration can range between about 5-50 mm, and the exact diameter is determined by the size of the false lumen 42 , which can vary anywhere between 5-20 mm.
  • the radial force exerted by the struts 16 , 24 of the intraluminal device 10 ranges from 0.1 to 10 N and helps secured the intraluminal device 10 within the false lumen 42 .
  • a filler material 64 may be inserted into the void formed by the expanded struts 16 , 24 .
  • the filler material 64 include: embolization coils, small intestinal submucosa (SIS), hydrogels, PETE, such as Dacron®, and microspheres.
  • SIS small intestinal submucosa
  • hydrogels PETE, such as Dacron®
  • microspheres MReye® is one type of embolization coil that may be inserted into the intraluminal device 10 .
  • MReye® is used for arterial and venous embolization in the peripheral vasculature and is manufactured by Cook Medical Inc., located in Bloomington, Ind.
  • the filler material 64 may be inserted into the cavity by a second catheter or through the same deployment device 48 that deployed the intraluminal device 10 within the false lumen 42 . In the alternative, the filler material 64 may be disposed within the intraluminal device 10 prior to being loaded onto the deployment device 48 .
  • the filler material 64 within the intraluminal device 10 encourages the thrombotic process to occur within the false lumen 42 .
  • an endovascular stent or a stent graft may be placed in the true lumen 43 in order to retain the patency of the true lumen 43 and encourage the thrombotic process.
  • Thrombosis will occur as a result of the filler material 64 causing turbulence and/or stagnation in the blood flow in the false lumen 42 .
  • the thrombosed area will grow, with the goal being to completely occlude the false lumen 42 from any pressurized blood blow. The blood flow will then be restored to the normal vessel pathway.
  • the intraluminal device 10 has a low plate stiffness in the range of 0.1 to 10 N, which is far less than the radial force generated by the increased blood pressure exerted (or a stent graft that may be placed) within the true lumen 43 . As a result, the intraluminal device 10 will begin to collapse as a result of the increased blood flow. The intraluminal device 10 will eventually achieve a low profile compressed configuration, as shown in FIG. 12 .
  • the intraluminal device 10 is wrapped in a membrane 80 , as shown in FIG. 13 .
  • the membrane 80 is made out of a Dacron polymer fiber.
  • the fibers are applied to the struts 16 of the intraluminal device 10 through a method referred to as electrospinning.
  • the membrane 80 prevents additional blood from entering the false lumen 42 and thereby decreasing the further propagation of the tear.
  • the membrane 80 may be made out of any suitable fiber, or material, that exhibits substantially the same properties as Dacron, including a hemostatic type of collagen or SIS.
  • the wrapping, or covering, process occurs via electrospinning when the intraluminal device 10 is in a compressed configuration. It is desired to perform the covering process when the intraluminal device 10 is in this configuration in order to prevent the covering to split apart when the intraluminal device 10 is compressed as it is loaded onto the deployment device.
  • a hemispherical ground plate is used during the electrospinning process to help attract fibers to the intraluminal device 10 being coated with the membrane 80 .
  • the hemispherical ground plate provides improved control of the location the fibers of the membrane 80 are coated on the intraluminal device 10 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Prostheses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Surgical Instruments (AREA)
US13/170,843 2010-07-20 2011-06-28 False lumen occluder Active 2032-01-02 US8876849B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/170,843 US8876849B2 (en) 2010-07-20 2011-06-28 False lumen occluder
EP11174324.1A EP2409655B1 (en) 2010-07-20 2011-07-18 False lumen occluder
JP2011158746A JP5912317B2 (ja) 2010-07-20 2011-07-20 偽腔オクルダー
CN201110208363.0A CN102415909B (zh) 2010-07-20 2011-07-20 假腔封堵器

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36595510P 2010-07-20 2010-07-20
US13/170,843 US8876849B2 (en) 2010-07-20 2011-06-28 False lumen occluder

Publications (2)

Publication Number Publication Date
US20120022573A1 US20120022573A1 (en) 2012-01-26
US8876849B2 true US8876849B2 (en) 2014-11-04

Family

ID=44512658

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/170,843 Active 2032-01-02 US8876849B2 (en) 2010-07-20 2011-06-28 False lumen occluder

Country Status (4)

Country Link
US (1) US8876849B2 (ar)
EP (1) EP2409655B1 (ar)
JP (1) JP5912317B2 (ar)
CN (1) CN102415909B (ar)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398441B2 (en) 2013-12-20 2019-09-03 Terumo Corporation Vascular occlusion
US10463470B2 (en) 2015-07-31 2019-11-05 Cook Medical Technologies Llc Methods of making a prosthesis with a smooth covering
US11564692B2 (en) 2018-11-01 2023-01-31 Terumo Corporation Occlusion systems
US12011174B2 (en) 2020-04-28 2024-06-18 Terumo Corporation Occlusion systems
US12023035B2 (en) 2017-05-25 2024-07-02 Terumo Corporation Adhesive occlusion systems

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012525239A (ja) 2009-05-01 2012-10-22 エンドロジックス、インク 解離を治療するための経皮的な方法および装置（優先権情報および参照による組み入れ）
US10772717B2 (en) 2009-05-01 2020-09-15 Endologix, Inc. Percutaneous method and device to treat dissections
WO2012068298A1 (en) * 2010-11-17 2012-05-24 Endologix, Inc. Devices and methods to treat vascular dissections
US20120172973A1 (en) * 2010-12-30 2012-07-05 Cook Medical Technologies Llc Self-expanding occlusion device
US8911468B2 (en) * 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
WO2015153507A1 (en) * 2014-03-31 2015-10-08 Spiration, Inc. Anchoring mechanisms and systems for endoluminal devices
CN105125250B (zh) * 2015-09-29 2017-04-05 中国人民解放军第二军医大学 辅助动脉瘤瘤颈的栓塞装置
US10524800B2 (en) * 2016-05-17 2020-01-07 The Cleveland Clinic Foundation Method and apparatus for substantially blocking bloodflow through a dissected aorta
CN107569300A (zh) * 2017-09-25 2018-01-12 上海长海医院 一种治疗主动脉夹层假腔的腔内修复移植物
CN108113785B (zh) * 2017-12-25 2020-04-21 有研医疗器械（北京）有限公司 一种血管内假腔封堵支架
CN114010241B (zh) * 2021-11-16 2023-12-22 复旦大学附属中山医院 一种用于主动脉夹层破口修复的封堵装置

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619246A (en) 1984-05-23 1986-10-28 William Cook, Europe A/S Collapsible filter basket
US5234458A (en) 1990-06-15 1993-08-10 Antheor Filter device intended to prevent embolisms
US5382259A (en) 1992-10-26 1995-01-17 Target Therapeutics, Inc. Vasoocclusion coil with attached tubular woven or braided fibrous covering
EP0882428A2 (en) 1997-06-05 1998-12-09 Arterial Vascular Engineering, Inc. Intravascular occlusion device
WO1999012484A1 (en) 1997-09-05 1999-03-18 Neurovasx, Inc. Vessel occlusion device
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
US5976174A (en) 1997-12-15 1999-11-02 Ruiz; Carlos E. Medical hole closure device and methods of use
US6193708B1 (en) 1997-08-05 2001-02-27 Scimed Life Systems, Inc. Detachable aneurysm neck bridge (I)
US6346117B1 (en) 2000-03-02 2002-02-12 Prodesco, Inc. Bag for use in the intravascular treatment of saccular aneurysms
US6368338B1 (en) 1999-03-05 2002-04-09 Board Of Regents, The University Of Texas Occlusion method and apparatus
US6428558B1 (en) 1999-03-10 2002-08-06 Cordis Corporation Aneurysm embolization device
US6636068B2 (en) 1998-05-22 2003-10-21 Micron Technology Inc Device and method for isolating a short-circuited integrated circuit (IC) from other ICs on a semiconductor wafer
US6740331B1 (en) 2000-08-25 2004-05-25 Global Gene Therapies, Inc. Apparatus for the delivery of drugs or gene therapy into a patient's vasculature and methods of use
US6746468B1 (en) 1999-06-02 2004-06-08 Concentric Medical, Inc. Devices and methods for treating vascular malformations
US20050165442A1 (en) * 2004-01-22 2005-07-28 Thinnes John H.Jr. Vein filter
US20070233178A1 (en) * 1999-05-07 2007-10-04 Salviac Limited Support frame for an embolic protection device
US20090138035A1 (en) 2005-09-22 2009-05-28 Takaaki Isshiki Filter for Thrombus Capture Catheter

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100400002C (zh) * 2003-07-03 2008-07-09 库克公司 用于堵塞流过体内管路的流体的封堵器
JP4531774B2 (ja) * 2004-02-04 2010-08-25 カラク アーゲー 体内の通路を閉塞するためのインプラント
DE102006013770A1 (de) * 2006-03-24 2007-09-27 Occlutech Gmbh Occlusionsinstrument und Verfahren zu dessen Herstellung
CN101449986B (zh) * 2007-11-28 2011-08-31 王涛 主动脉导管未闭的阻塞器
WO2010022072A2 (en) * 2008-08-18 2010-02-25 Cook Incorporated Occluding device and method of occluding fluid flow through a body vessel
WO2011094638A1 (en) * 2010-01-28 2011-08-04 Micro Therapeutics, Inc. Vascular remodeling device

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619246A (en) 1984-05-23 1986-10-28 William Cook, Europe A/S Collapsible filter basket
US5234458A (en) 1990-06-15 1993-08-10 Antheor Filter device intended to prevent embolisms
US5382259A (en) 1992-10-26 1995-01-17 Target Therapeutics, Inc. Vasoocclusion coil with attached tubular woven or braided fibrous covering
EP0882428A2 (en) 1997-06-05 1998-12-09 Arterial Vascular Engineering, Inc. Intravascular occlusion device
US6193708B1 (en) 1997-08-05 2001-02-27 Scimed Life Systems, Inc. Detachable aneurysm neck bridge (I)
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
WO1999012484A1 (en) 1997-09-05 1999-03-18 Neurovasx, Inc. Vessel occlusion device
US5976174A (en) 1997-12-15 1999-11-02 Ruiz; Carlos E. Medical hole closure device and methods of use
US6636068B2 (en) 1998-05-22 2003-10-21 Micron Technology Inc Device and method for isolating a short-circuited integrated circuit (IC) from other ICs on a semiconductor wafer
US6368338B1 (en) 1999-03-05 2002-04-09 Board Of Regents, The University Of Texas Occlusion method and apparatus
US6428558B1 (en) 1999-03-10 2002-08-06 Cordis Corporation Aneurysm embolization device
US20070233178A1 (en) * 1999-05-07 2007-10-04 Salviac Limited Support frame for an embolic protection device
US6746468B1 (en) 1999-06-02 2004-06-08 Concentric Medical, Inc. Devices and methods for treating vascular malformations
US6346117B1 (en) 2000-03-02 2002-02-12 Prodesco, Inc. Bag for use in the intravascular treatment of saccular aneurysms
US6740331B1 (en) 2000-08-25 2004-05-25 Global Gene Therapies, Inc. Apparatus for the delivery of drugs or gene therapy into a patient's vasculature and methods of use
US7648495B2 (en) 2000-08-25 2010-01-19 Nexeon Medsystems, Inc. Apparatus for the delivery of drugs or gene therapy into a patient's vasculature and methods of use
US20050165442A1 (en) * 2004-01-22 2005-07-28 Thinnes John H.Jr. Vein filter
US20090138035A1 (en) 2005-09-22 2009-05-28 Takaaki Isshiki Filter for Thrombus Capture Catheter

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10398441B2 (en) 2013-12-20 2019-09-03 Terumo Corporation Vascular occlusion
US11832824B2 (en) 2013-12-20 2023-12-05 Terumo Corporation Vascular occlusion
US10463470B2 (en) 2015-07-31 2019-11-05 Cook Medical Technologies Llc Methods of making a prosthesis with a smooth covering
US12023035B2 (en) 2017-05-25 2024-07-02 Terumo Corporation Adhesive occlusion systems
US11564692B2 (en) 2018-11-01 2023-01-31 Terumo Corporation Occlusion systems
US12011174B2 (en) 2020-04-28 2024-06-18 Terumo Corporation Occlusion systems

Also Published As

Publication number Publication date
CN102415909B (zh) 2015-09-16
JP5912317B2 (ja) 2016-04-27
CN102415909A (zh) 2012-04-18
EP2409655B1 (en) 2017-04-05
JP2012030068A (ja) 2012-02-16
EP2409655A2 (en) 2012-01-25
US20120022573A1 (en) 2012-01-26
EP2409655A3 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
US8876849B2 (en) False lumen occluder
US10828183B2 (en) Low profile non-symmetrical stent
US8747453B2 (en) Stent/stent graft for reinforcement of vascular abnormalities and associated method
US8163004B2 (en) Stent graft for reinforcement of vascular abnormalities and associated method
JP6106143B2 (ja) ステント部材
US8740966B2 (en) Low profile non-symmetrical stent
US7674284B2 (en) Endoluminal graft
US8728145B2 (en) Low profile non-symmetrical stents and stent-grafts
US20130204351A1 (en) Aneurysm Graft Devices And Methods
US20160030155A1 (en) Aneurysm Graft With Stabilization
US20210015599A1 (en) Stent graft
US11986189B2 (en) Systems and methods for treating aneurysms

Legal Events

Date Code Title Description
AS Assignment

Owner name: COOK MEDICAL TECHNOLOGIES LLC, INDIANA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC.;REEL/FRAME:027048/0273

Effective date: 20110922

Owner name: MEDICAL ENGINEERING AND DEVELOPMENT INSTITUTE, INC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KRATZBERG, JARIN;GOPAL, SHARATH;PURDY, JAMES D.;AND OTHERS;SIGNING DATES FROM 20110712 TO 20110913;REEL/FRAME:027048/0150

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551)

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, DELAWARE

Free format text: SECURITY INTEREST;ASSIGNOR:COOK MEDICAL TECHNOLOGIES LLC;REEL/FRAME:066700/0277

Effective date: 20240227